ArticleHeliyon2024
Development and characterization of high-affinity aptamers for HIV protease detection.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- EpiMolBio: A novel user-friendly bioinformatic program for genetic variability analysis.Computational and structural biotechnology journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There are 39 million people infected by the human immunodeficiency virus (HIV) and 1.3 million new annually infections with more than 150 variants circulating. Early HIV detection is crucial for timely antiretroviral therapy and transmission prevention, but no technique can detect HIV before 10 days of infection. Aptamers, single-stranded oligonucleotides, can recognize specific proteins with high affinity and specificity. New molecular assays based on aptamers selected against highly-conserved peptides in HIV proteins could help to detect the virus earlier. Results: We have selected and characterized the first two aptamers against a highly-conserved and exposed peptide in the HIV protease (PR) after analyzing 236,240/6,436 HIV-1/HIV-2 PR sequences of nearly 150 HIV variants (types/groups/subtypes/circulating recombinants) by new bioinformatics tools. The selected aptamers were characterized by bioinformatics analysis, exploring their affinity, sensitivity, specificity, and best combination by Enzyme-Linked-Oligonucleotide-Assays (ELONA). Different strategies were explored to increase sensitivity for HIV PR detection, and the best one could detect viral PR (3.13 ng, 3.76·10 Significance: Our anti-HIV PR aptamers are a promissing tool to be incorporated into new nanotechnologies for an ultrasensitive detection of HIV proteins in clinical samples for an early diagnosis of all virus variants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.